- Home
- GLMD vs OGEN Comparison
GLMD vs OGEN Comparison
Compare GLMD & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- OGEN
- Stock Information
- Founded
- GLMD 2000
- OGEN 1996
- Country
- GLMD Israel
- OGEN United States
- Employees
- GLMD N/A
- OGEN N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- OGEN Health Care
- Exchange
- GLMD Nasdaq
- OGEN Nasdaq
- Market Cap
- GLMD 4.5M
- OGEN 3.9M
- IPO Year
- GLMD 2014
- OGEN N/A
- Fundamental
- Price
- GLMD $2.70
- OGEN $0.29
- Analyst Decision
- GLMD
- OGEN
- Analyst Count
- GLMD 0
- OGEN 0
- Target Price
- GLMD N/A
- OGEN N/A
- AVG Volume (30 Days)
- GLMD 21.6K
- OGEN 14.3M
- Earning Date
- GLMD 04-03-2025
- OGEN 03-28-2025
- Dividend Yield
- GLMD N/A
- OGEN N/A
- EPS Growth
- GLMD N/A
- OGEN N/A
- EPS
- GLMD N/A
- OGEN N/A
- Revenue
- GLMD N/A
- OGEN N/A
- Revenue This Year
- GLMD N/A
- OGEN N/A
- Revenue Next Year
- GLMD N/A
- OGEN N/A
- P/E Ratio
- GLMD N/A
- OGEN N/A
- Revenue Growth
- GLMD N/A
- OGEN N/A
- 52 Week Low
- GLMD $2.24
- OGEN $0.25
- 52 Week High
- GLMD $23.80
- OGEN $3.84
- Technical
- Relative Strength Index (RSI)
- GLMD 49.41
- OGEN 46.16
- Support Level
- GLMD $2.24
- OGEN $0.28
- Resistance Level
- GLMD $2.72
- OGEN $0.31
- Average True Range (ATR)
- GLMD 0.20
- OGEN 0.05
- MACD
- GLMD 0.02
- OGEN 0.00
- Stochastic Oscillator
- GLMD 71.47
- OGEN 9.39
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.